Atherosclerotic renovascular disease in chronic heart failure: should we intervene?

被引:40
作者
de Silva, R
Nikitin, NP
Bhandari, S
Nicholson, A
Clark, AL
Cleland, JGF
机构
[1] Univ Hull, Castle Hill Hosp, Acad Cardiol, Cottingham HU16 5JQ, E Yorkshire, England
[2] Hull Royal Infirm, Dept Nephrol, Kingston Upon Hull HU3 2JZ, E Yorkshire, England
[3] Gen Infirm, Dept Vasc Radiol, Leeds LS1 3EX, W Yorkshire, England
关键词
heart failure; renovascular disease; intervention;
D O I
10.1093/eurheartj/ehi304
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Renal artery stenosis (RAS) is most commonly caused by atherosclerosis, which is also the most common cause of chronic heart failure (CHF). One-third of patients with CHF are reported to have significant renovascular disease. The presence of RAS confers a worse outcome in studies of hypertension and coronary disease, though data are lacking for patients with CHE As the kidney is intricately involved in the fluid retention that occurs in CHF, an adverse effect of RAS on outcome would be expected. Presentations of RAS in CHF include flash pulmonary oedema, hypertension, worsening of CHF, and worsening renal function. RAS commonly progresses and may cause worsening of renal function in patients with CHF and previously stable renal function. A variety of investigations that can safety and accurately identify RAS in CHF are available, although none is recommended in current guidelines for the management of CHE Treatment for RAS, whether for hypertension, for renal dysfunction, or for pulmonary oedema, is at the discretion of the physician due to the lack of adequate randomized controlled trials demonstrating the efficacy and safety of intervention. As it is not clear how RAS should be managed in CHF, screening cannot be advocated. Currently, a multicentre randomized outcome trial, which includes a cohort of patients with RAS and CHF, is in progress to provide answers in this area of uncertainty.
引用
收藏
页码:1596 / 1605
页数:10
相关论文
共 152 条
[31]   Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis [J].
Dorros, G ;
Jaff, M ;
Mathiak, L ;
Dorros, II ;
Lowe, A ;
Murphy, K ;
He, T .
CIRCULATION, 1998, 98 (07) :642-647
[32]   The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction [J].
Dries, DL ;
Exner, DV ;
Domanski, MJ ;
Greenberg, B ;
Stevenson, LW .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 35 (03) :681-689
[33]  
Duclos J, 2002, REV MED CHILE, V130, P1033
[34]  
Ducloux D, 1997, CLIN NEPHROL, V48, P54
[35]   Atherosclerotic renal artery stenosis: is it worth diagnosing? [J].
Eardley, KS ;
Lipkin, GW .
JOURNAL OF HUMAN HYPERTENSION, 1999, 13 (04) :217-220
[36]  
Edwards Matthew S, 2004, Vasc Endovascular Surg, V38, P25, DOI 10.1177/153857440403800103
[37]   'Flash pulmonary oedema' in a patient 24 years after aorto-renal vein graft [J].
Farmer, CKT ;
Reidy, J ;
Scoble, JE .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (05) :1310-1312
[38]   Percutaneous intervention for renovascular disease: rationale and patient selection [J].
Fernando, D ;
Garasic, J .
CURRENT OPINION IN CARDIOLOGY, 2004, 19 (06) :582-588
[39]   Reduced spontaneous baroreceptor sensitivity in patients with renovascular hypertension [J].
Gao, SA ;
Johansson, M ;
Rundqvist, B ;
Lambert, G ;
Jensen, G ;
Friberg, P .
JOURNAL OF HYPERTENSION, 2002, 20 (01) :111-116
[40]  
Geddes C C, 2002, Minerva Urol Nefrol, V54, P29